
CARL SARGEANT AM AWAITS HEALTH EXPERT GROUP RECOMMENDATIONS
Carl Sargeant, AM for Alyn and Deeside, is welcoming the news that an expert group set up by Health Minister Edwina Hart to look at the issues around funding drugs on the NHS that are not approved by NICE will report on its findings and recommendations in the New Year. The group, led by Professor Philip Routledge, the chair of the All Wales Medicines Strategy Group, has been canvassing views of health professionals and patient representatives over the summer. Mr Sargeant said: “NICE has an extremely difficult job to do in determining the clinical and cost effectiveness of new drugs. In most cases their determination is accepted, although there are occasions when their decisions are unpopular, or when they give patients and clinicians cause for concern - such as access to Lucentis for Wet AMD and drugs for kidney cancer. “Access to treatment is a very serious matter, about which people have very strong opinions. I hope will have clinical need and patient care and benefit at the forefront of their deliberations, and I look forward to reading their recommendations.”The group will look into the potential difficulties surrounding the provision of drugs that do not hold NICE approval. It will engage with the leading clinicians across Wales and, in particular, with those involved in cancer care. As well as considering how the ‘non-approved’ or ‘decision pending’ drug issue might be handled in an ethical and fair manner, the group will consider the matter of life-prolonging treatments that are prescribed in the last months of life, often at great expense but with little hope of success.
Carl Sargeant, AM for Alyn and Deeside, is welcoming the news that an expert group set up by Health Minister Edwina Hart to look at the issues around funding drugs on the NHS that are not approved by NICE will report on its findings and recommendations in the New Year. The group, led by Professor Philip Routledge, the chair of the All Wales Medicines Strategy Group, has been canvassing views of health professionals and patient representatives over the summer. Mr Sargeant said: “NICE has an extremely difficult job to do in determining the clinical and cost effectiveness of new drugs. In most cases their determination is accepted, although there are occasions when their decisions are unpopular, or when they give patients and clinicians cause for concern - such as access to Lucentis for Wet AMD and drugs for kidney cancer. “Access to treatment is a very serious matter, about which people have very strong opinions. I hope will have clinical need and patient care and benefit at the forefront of their deliberations, and I look forward to reading their recommendations.”The group will look into the potential difficulties surrounding the provision of drugs that do not hold NICE approval. It will engage with the leading clinicians across Wales and, in particular, with those involved in cancer care. As well as considering how the ‘non-approved’ or ‘decision pending’ drug issue might be handled in an ethical and fair manner, the group will consider the matter of life-prolonging treatments that are prescribed in the last months of life, often at great expense but with little hope of success.









